Correction: Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.

Correction: Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.

Bibliographic Details
Main Authors:	Haixiu Guo, Xiuhua Chen, Ruiyuan Tian, Jianmei Chang, Jianlan Li, Yanhong Tan, Zhifang Xu, Fanggang Ren, Junxia Zhao, Jie Pan, Na Zhang, Xiaojuan Wang, Jianxia He, Wanfang Yang, Hongwei Wang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4607294?pdf=render

Similar Items

Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
by: Haixiu Guo, et al.
Published: (2015-01-01)

CALR Mutations in Myeloproliferative Neoplasms
by: Ken-Hong Lim
Published: (2014-06-01)

FREQUENCY OF CALR GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
by: Sana Latif, et al.
Published: (2020-04-01)

Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm
by: Fraiman YS, et al.
Published: (2016-05-01)

JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms
by: Shuichi Shirane, et al.
Published: (2015-02-01)

Effects of <i>CALR</i>-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms
by: Hyun-Young Kim, et al.
Published: (2022-10-01)

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
by: Keiji Minakawa, et al.
Published: (2021-03-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease
by: Anna Stengel, et al.
Published: (2019-05-01)

Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
by: Velizar Shivarov, et al.
Published: (2024-09-01)

Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms
by: Hejer Elmahmoudi, et al.
Published: (2023-01-01)

Granulocytic sarcoma: Extramedullary manifestation of chronic myeloproliferative neoplasm in a young African woman
by: Ajayi A. Ibijola, et al.
Published: (2021-03-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01)

JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms
by: Waihay J. Wong, et al.
Published: (2018-02-01)

Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease
by: Magda Zanelli, et al.
Published: (2024-03-01)

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01)

Myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable; rare cause of granulocytic sarcoma: A diagnostic dilemma
by: Prakas Kumar Mandal, et al.
Published: (2016-01-01)

Myeloproliferative neoplasms
by: Nick Cross, (Coordinating Author)
Published: (2019-06-01)

Myeloproliferative neoplasms
by: Jean-Jacques Kiladjian
Published: (2018-06-01)

Molecular Diagnostics with Laboratory Finding in Patients with Myeloproliferative Neoplasms
by: Zahra MAKANI, et al.
Published: (2017-11-01)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
by: Li Huo, et al.
Published: (2023-01-01)

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms
by: Luca Malcovati, et al.
Published: (2014-11-01)

The microenvironment in myeloproliferative neoplasm
by: Simón Méndez-Ferrer, et al.
Published: (2018-06-01)

Spleen in myeloproliferative neoplasms
by: Giovanni Barosi
Published: (2018-06-01)

Epigenetics in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2023-07-01)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
by: Kathrin Olschok, et al.
Published: (2023-10-01)

Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing
by: Arti Easwar, et al.
Published: (2021-10-01)

Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
by: Ella R. Thompson, et al.
Published: (2020-08-01)

Myeloproliferative neoplasm stem cells
by: Mead, A, et al.
Published: (2017)

The Hematopoietic Niche in Myeloproliferative Neoplasms
by: Annette H. Schmitt-Graeff, et al.
Published: (2015-01-01)

Pathophysiology of thrombosis in myeloproliferative neoplasms
by: Raffaele Landolfi, et al.
Published: (2011-02-01)

Autoimmunity and the risk of myeloproliferative neoplasms
by: Sigurdur Y. Kristinsson, et al.
Published: (2010-07-01)

Interferons in the treatment of myeloproliferative neoplasms
by: Pankit Vachhani, et al.
Published: (2024-02-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
by: Daniel Prins, et al.
Published: (2020-02-01)

Neurological Findings in Myeloproliferative Neoplasms
by: Semra Paydas
Published: (2013-04-01)

Novel therapeutics in myeloproliferative neoplasms
by: Sangeetha Venugopal, et al.
Published: (2020-12-01)

Targeted therapies for myeloproliferative neoplasms
by: Bing Li, et al.
Published: (2019-07-01)

Molecular pathogenesis of the myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2021-06-01)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
by: Kathrin Olschok, et al.
Published: (2023-08-01)

A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia
by: Zhuanghui Hao, et al.
Published: (2024-01-01)